Navigation Links
MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
Date:2/11/2009

VALENCIA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2008 fourth quarter financial results on Tuesday, February 17, 2009.

Management of the Company will host a conference call to discuss the fourth quarter financial results, clinical progress and other Company developments at 4:00 p.m. ET on Tuesday, February 17, 2009. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the internet may do so by visiting the Company's website at http://www.mannkindcorp.com. The web site replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (800) 756-2759 or (402) 998-0791.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in Phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at http://www.mannkindcorp.com'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
2. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
3. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
4. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
5. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
6. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
7. MannKind to Present at the UBS Global Life Sciences Conference
8. MannKind Corporation Reports Second Quarter Financial Results
9. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
10. MannKind to Present at Upcoming Conferences
11. MannKind Corporation Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015  The Paul G. Allen ... Investigator (ADI) grants to six groups of researchers with ... challenging roadblocks in neuroscience: growing mature human brain cells ... total of $7.5 million over three years.  ... their research is especially significant because the field of ...
(Date:4/30/2015)... 2015 Available in select spas ... , Fleur’s introduces CC CRÈME ... benefits of makeup, skin care and solar protection ... is designed with specific complexion-correcting pigments to instantly ... and a healthy glow. Far more than a ...
(Date:4/29/2015)... 2015 According to a new ... Product (Portable & Non-Portable), Component (Accelerometer, Proximity Probe, ... Metal & Mining, & Others), & Geography - ... expected to reach $1,453.76 Million by 2020, at ... data tables and 92 figures spread through 205 ...
(Date:4/29/2015)... AlloSource ®, one of the ... and soft-tissue allografts for use in surgical procedures ... the launch of AlloSkin™ AC, an acellular dermal ... (CMS) also moved AlloSkin™ RT, a meshed human ... category for reimbursement. "AlloSource is committed ...
Breaking Biology Technology:The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4AlloSource Announces New Possibilities In Wound Care 2
... , June 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ... been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for ... for treating cell proliferative disorders by administering modified vaccinia virus to ... , , ...
... June 17 ChemoCentryx, Inc., today announced that ... drug candidate CCX354 at the Annual European Congress of ... drug candidate designed to specifically target the CCR1 chemokine ... (RA).  Data demonstrating that CCX354 was safe and well ...
... Researchers at Rensselaer Polytechnic Institute have developed a ... that measure only billionths of a meter thick. ... works on nearly any surface including silicon wafers, ... manufacturing. Sang-Kee Eah, assistant professor in the ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent 2ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 2ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 3ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 4Researchers develop ultra-simple method for creating nanoscale gold coatings 2
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)... OXFORD, Conn. , Mar. 23, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, announces ... a new advertising campaign on CNBC television starting March 30 ... ads will commence airing in New York ... Executive Officer said: "We are excited about our new ad ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... 24, 2013 For the first time, scientists at ... moderate-severe traumatic brain injury (TBI), atrophy (shrinkage) in the ... increased physical, social and cognitive stimulation. The ... in the chronic stages of traumatic brain injury," was ...
... (Sept. 24, 2013) Retinal (or fundus) photography is ... cameras can cost tens to hundreds of thousands of ... ophthalmic practices and to physicians in third-world countries. In ... Ear researchers describe the relatively simple technique of fundus ...
... researchers have identified and validated two rare gene mutations that ... that strikes after the age of 60. The two mutations ... enzyme involved in processing the amyloid precursor protein which ... the fifth AD gene overall. In their ...
Cached Biology News:Scientists discover environmental enrichment for TBI patients may counter shrinkage in the brain 2Scientists discover environmental enrichment for TBI patients may counter shrinkage in the brain 3Researchers use smart phone photography to diagnose eye disease 2Study confirms that rare mutations increase risk of late-onset Alzheimer's disease 2Study confirms that rare mutations increase risk of late-onset Alzheimer's disease 3
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Mouse anti-Cytohesin 2, Monoclonal Antibody, Unconjugated ... assay dependent dilution. ICC: Use at an assay ... 5 - 10 ug/ml, this concentration is determined ... molecular weight: 40 kDa. Not tested in other ...
SHP-2 Antibody...
... Transporter 2, Neuronal (GLYT2). The antiserum has ... central nervous system. The staining pattern obtained ... using in situ hybridization with probes to ... described for glycinergic neurons. Preabsorption of the ...
Biology Products: